Spots Global Cancer Trial Database for human papillomavirus vaccine

Every month we try and update this database with for human papillomavirus vaccine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis	NCT00829608	Recurrent Respi...	Human Papilloma...	18 Years - 80 Years	University of Missouri-Columbia
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)	NCT01047345	Cervical Cancer... Vulvar Cancers Vaginal Cancers Genital Warts	V503 Placebo to V503	12 Years - 26 Years	Merck Sharp & Dohme LLC
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL	NCT01928225	Cervical High G...	Human Papilloma...	18 Years -	University of Witwatersrand, South Africa
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	NCT04537156	Cervical Intrae... Cervical Cancer Condylomata Acu...	Nonavalent HPV ... Bivalent HPV va...	18 Years - 45 Years	Xiamen University
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects	NCT03438006	Cervical Intrae...	Safety data col...	9 Years - 45 Years	GlaxoSmithKline
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL	NCT01928225	Cervical High G...	Human Papilloma...	18 Years -	University of Witwatersrand, South Africa
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age	NCT04782895	Cervical Cancer Condylomata Acu...	Recombinant Hum... Gardasil®9	18 Years - 26 Years	Xiamen University
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects	NCT03438006	Cervical Intrae...	Safety data col...	9 Years - 45 Years	GlaxoSmithKline
Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka	NCT01551537	Human Papilloma...	Cervarix data c... Data Collection	10 Years -	GlaxoSmithKline
The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients	NCT00767897	Chronic Kidney ... Dialysis	Human Papilloma...	9 Years - 18 Years	Indiana University
A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea	NCT03671369	Neoplasms, Rect...	Safety data col...	9 Years - 25 Years	GlaxoSmithKline
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age	NCT04782895	Cervical Cancer Condylomata Acu...	Recombinant Hum... Gardasil®9	18 Years - 26 Years	Xiamen University
mHealth Intervention in Increasing HPV Vaccinations in College Students	NCT02960100	Healthy Subject	Informational I... Media Intervent... Survey Administ...	18 Years - 25 Years	Ohio State University Comprehensive Cancer Center
Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers	NCT00925288	Human Papilloma...	Gardasil	18 Years - 26 Years	Johns Hopkins Bloomberg School of Public Health
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis	NCT00829608	Recurrent Respi...	Human Papilloma...	18 Years - 80 Years	University of Missouri-Columbia
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL	NCT01928225	Cervical High G...	Human Papilloma...	18 Years -	University of Witwatersrand, South Africa
A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea	NCT03671369	Neoplasms, Rect...	Safety data col...	9 Years - 25 Years	GlaxoSmithKline

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: